← Eichor
Study identifier: NCT06380504 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Increasing the Coverage of Severe Acute Malnutrition (SAM) Treatment in Ethiopia

Condition: Acute Malnutrition, Severe · Malnutrition, Child · Wasting  ·  Sponsor: International Food Policy Research Institute

PhaseNA
Planned participants1080
Who can joinAll sexes, 6 Months to 5 Years
Healthy volunteersYes

About this study

The R-SWITCH intervention aims to address the low coverage of treatment for severe wasting (SAM) by leveraging existing community groups to deliver an integrated package focused on prevention, screening, referral, and treatment of SAM. It includes behavior change communication on child nutrition and health, active screening, improved passive screening at health posts, and follow-up of referred cases and those enrolled in outpatient treatment programs (OTP). The primary objectives of the R-SWITCH studies are to assess the intervention's impact on OTP coverage, identify implementation barriers and facilitators, and evaluate its cost-efficiency and cost-effectiveness.

This description comes directly from the study's public registry record.

Talk to the study team

Lieven Huybregts, PhD  ·  202 862-6481  ·  l.huybregts@cgiar.org

Alemayehu Haddis, PhD  ·  alemayehuh@etpha.org

Always discuss trial participation with your own doctor first.

Locations (1)

Kersa and Jeldessa woredasJimma, EthiopiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06380504